Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

Regulation of carbamoyl phosphate synthetase by MAP kinase

Interplay between mTOR and Purine Metabolism Enzymes and Its Relevant Role in Cancer

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

The mTORC1-SLC4A7 axis stimulates bicarbonate import to enhance de novo nucleotide synthesis

mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis

Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

The Molecular Determinants of De Novo Nucleotide Biosynthesis in Cancer Cells

Advances in the Mechanisms of Amino Acid Signaling in mTORC1 Pathway

Target of Rapamycin (TOR) Regulates Growth in Response to Nutritional Signals

Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy

Pyruvate Kinase M2 Promotes De Novo Serine Synthesis to Sustain Mtorc1 Activity and Cell Proliferation.

Nuclear mTOR Signaling Orchestrates Transcriptional Programs Underlying Cellular Growth and Metabolism

Breakdown of the regulatory control of pyrimidine biosynthesis in human breast cancer cells

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling

FSMP-08. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS

Ribosomal S6 kinase signaling and the control of translation.